← Back to Screener
Precipio, Inc. Common Stock (PRPO)
Price$28.15
Favorite Metrics
Price vs S&P 500 (26W)39.90%
Price vs S&P 500 (4W)-7.99%
Market Capitalization$50.21M
All Metrics
P/CF (Annual)114.38x
Book Value / Share (Quarterly)$7.88
P/TBV (Annual)36.50x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)27.94%
Cash Flow / Share (Quarterly)$0.34
Price vs S&P 500 (YTD)19.01%
Gross Margin (TTM)44.82%
Net Profit Margin (TTM)-5.50%
EPS (TTM)$-0.83
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-0.83
Revenue Growth (5Y)42.72%
EPS (Annual)$-2.93
ROI (Annual)-33.15%
Gross Margin (Annual)40.79%
Net Profit Margin (5Y Avg)-92.45%
Cash / Share (Quarterly)$1.32
Revenue Growth QoQ (YoY)29.91%
ROA (Last FY)-25.24%
Revenue Growth TTM (YoY)30.95%
EBITD / Share (TTM)$0.15
ROE (5Y Avg)-52.16%
Operating Margin (TTM)-8.50%
Cash Flow / Share (Annual)$0.14
P/B Ratio3.65x
P/B Ratio (Quarterly)2.10x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.15x
Net Interest Coverage (TTM)-56.97x
ROA (TTM)-6.71%
EV / EBITDA (TTM)215.88x
EPS Incl Extra (Annual)$-2.93
Current Ratio (Annual)0.81x
Quick Ratio (Quarterly)1.10x
3-Month Avg Trading Volume0.02M
52-Week Price Return405.36%
EV / Free Cash Flow (Annual)226.87x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.48
P/S Ratio (Annual)2.71x
Asset Turnover (Annual)1.09x
52-Week High$29.80
Operating Margin (5Y Avg)-93.07%
EPS Excl Extra (Annual)$-2.93
CapEx CAGR (5Y)30.03%
Tangible BV CAGR (5Y)-36.90%
26-Week Price Return48.65%
Quick Ratio (Annual)0.57x
13-Week Price Return17.92%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)1.27x
Enterprise Value$49.005
Revenue / Share Growth (5Y)2.50%
Asset Turnover (TTM)1.22x
Book Value / Share Growth (5Y)-24.88%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)19.81x
Pretax Margin (Annual)-23.15%
Cash / Share (Annual)$0.93
3-Month Return Std Dev62.92%
Gross Margin (5Y Avg)30.59%
Net Income / Employee (TTM)$-0
ROE (Last FY)-35.47%
Net Interest Coverage (Annual)-13.58x
EPS Basic Excl Extra (Annual)$-2.93
P/FCF (TTM)61.61x
Receivables Turnover (TTM)15.31x
EV / Free Cash Flow (TTM)83.20x
Total Debt / Equity (Quarterly)0.08x
EPS Incl Extra (TTM)$-0.83
Receivables Turnover (Annual)17.65x
ROI (TTM)-9.42%
P/S Ratio (TTM)2.20x
Pretax Margin (5Y Avg)-92.29%
Revenue / Share (Annual)$12.65
Tangible BV / Share (Annual)$0.15
Forward P/E0.95x
Price vs S&P 500 (52W)370.26%
Year-to-Date Return23.15%
5-Day Price Return0.89%
EPS Normalized (Annual)$-2.93
ROA (5Y Avg)-38.73%
Net Profit Margin (Annual)-23.15%
Month-to-Date Return13.20%
Cash Flow / Share (TTM)$-6.37
EBITD / Share (Annual)$-1.99
Operating Margin (Annual)-22.75%
LT Debt / Equity (Annual)0.01x
P/CF (TTM)56.80x
ROI (5Y Avg)-49.57%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.83
P/TBV (Quarterly)11.12x
P/B Ratio (Annual)0.68x
Inventory Turnover (TTM)18.26x
Pretax Margin (TTM)-5.50%
Book Value / Share (Annual)$8.10
Price vs S&P 500 (13W)15.05%
Beta1.38x
P/FCF (Annual)232.46x
Revenue / Share (TTM)$13.92
ROE (TTM)-10.07%
52-Week Low$5.09
Analyst Recommendations
Mar 2024
Apr 2024
May 2024
Jun 2024
4.14
4.14
4.14
4.14
Industry Peers — Lab Analytical Instruments(22)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
PRPOPrecipio, Inc. Common Stock | 2.20x | 42.72% | 44.82% | -8.50% | $28.15 |
AAgilent Technologies Inc. | 4.83x | 5.41% | 52.60% | 20.40% | $120.96 |
WATWaters Corp | 10.18x | 6.00% | 59.28% | 25.36% | $335.61 |
MTDMettler-Toledo International | 6.66x | 5.47% | 59.37% | 26.05% | $1324.66 |
ILMNIllumina Inc | 4.69x | 6.04% | 66.61% | 18.44% | $132.86 |
RVTYRevvity, Inc. | 3.64x | -5.46% | 54.77% | 12.49% | $93.03 |
BIOBio-Rad Laboratories, Inc.Class A | 3.17x | 0.29% | 52.01% | 1.59% | $303.34 |
BIO.BBio-Rad Laboratories, Inc. Class B | 3.17x | 0.29% | 52.01% | 1.59% | $277.00 |
BRKRBruker Corporation | 1.81x | 11.57% | 47.13% | 1.40% | $41.10 |
BRKRPBruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | 1.81x | 11.57% | 47.13% | 1.40% | $320.13 |
AVTRAvantor, Inc. | 0.88x | 0.49% | 32.65% | -3.83% | $8.50 |
About
Precipio Inc develops blood cancer diagnostics designed to reduce misdiagnoses among office-based oncologists. The company operates CLIA-certified laboratories in Connecticut and Nebraska, offering diagnostic products including HemeScreen and IV-Cell to healthcare providers across the United States. Revenue is primarily generated from third-party payers.